> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-113/
- Published: 2018-09-23T12:00:00.000Z
- Updated: 2026-09-15T00:33:33.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141428

**Eli Lilly** has agreed to acquire **AurKa Pharma**, a company established by **TVM Capital Life Science** to develop oncology compound AK-01, an Aurora kinase A inhibitor that was originally discovered at Lilly. The potential first-in-class drug is being studied in Phase 1 clinical trials in multiple types of solid tumors. Aurora kinases are believed to play a crucial role in cellular division by controlling chromosomal segregation.

**Amneal** has acquired **Gemini Laboratories**, a company focused on branded pharmaceuticals, for $117 million. Gemini’s lead product is Unithroid to treat hypothyroidism. Amneal also entered into a licensing agreement for the U.S. market with Spanish company **MabXience SL** for its biosimilar candidate for **Roche**’s Avastin (bevacizumab).

**Surmodics** has reached an agreement with **Embolitech** to acquire an innovative thrombectomy platform technology and related intellectual property with broad potential peripheral vascular applications. Under the agreement, Surmodics will pay $5 million up front, and additional amounts related to various regulatory milestones. The Embolitech technology platform is designed to remove difficult, organized (hard) blood clots.